George Millen: Unscripted

The newly public logistics firm reports soaring H1 2025 profits and revenue, yet its stock price tells a different, more cautious story.

A landmark executive order reclassifying cannabis is set to unleash a wave of biopharma innovation, validating science-first firms like Avicanna.

The Canadian retailer's Q3 results show strong sales growth, but a sharp drop in net earnings reveals the high price of its ambitious turnaround plan.

Titan Mining's new funding aims to end a 70-year U.S. graphite production gap, a critical move for the nation's EV and energy independence goals.

Industrial giant Fastenal partners with the Belfast Giants, a strategic move blending global business ambition with deep-rooted community engagement in NI.

Facing a critical cash shortfall, Cue Biopharma turns to the market, betting its promising cancer and autoimmune pipeline can win over investors.

Baylin Technologies raises key funds for its transformative Kaelus AB acquisition, a strategic move aimed at growth that also puts shareholder governance in focus.

With a massive potential loan, the U.S. government is backing a plan to mine in Alaska and manufacture in Ohio, aiming to end its reliance on foreign graphite.

ICL Group's deal to acquire acidulant leader Bartek Ingredients signals a major push into the booming functional food market, leveraging unique production.

YXT.com's $100M shelf registration gives it a war chest for AI growth, but investors weigh the promise of innovation against current financial pressures.

Former Google CEO Eric Schmidt's new venture, Bolt, partners with Texas landowner TPL to build a massive AI data center hub in the Permian Basin.

Nav's new pilot empowers small businesses to extend trade credit, but can its community-focused model stand out in a growing market for B2B payments?

The pet and garden giant expands its animal health portfolio, acquiring a leader in eco-friendly cattle fly control to strengthen its position in a growing market.

Rail Vision just secured a key European patent for its AI collision avoidance tech. Is this IP fortress enough to challenge giants and define the future of rail?

After a NYSE delisting, FOXO Technologies is betting big on healthcare acquisitions. Is this a savvy turnaround or a high-risk gamble for investors?

The junior explorer is expanding its footprint in a hot gold district. We analyze the financial mechanics, shareholder impact, and leadership incentives.

Greenway Technologies is leaving the lab. A new deal with a Native-owned firm aims to turn stranded gas into gold, but can the micro-plant economics work?

Aligos Therapeutics is using strategic stock grants to lure top talent. Is this a savvy growth play or a creeping cost for shareholders? We break it down.

SEALSQ appoints public-private partnership veteran Rolf Gobet to lead its new Geneva Quantum Center, a key move in a well-funded race against quantum threats.

Datavault AI is issuing a 'meme coin' to shareholders. Is this the future of corporate rewards or a regulatory tightrope walk with a speculative asset?